

ALLIA.143C1



#14  
Jm  
1/11/03  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Zaghouani, H.	)	Group Art Unit 1644
			)	
Appl. No.	:	09/623,728	)	I hereby certify that this correspondence and
			)	all marked attachments are being deposited
Filed	:	January 22, 2001	)	with the United States Postal Service as first
			)	class mail in an envelope addressed to:
For	:	Compounds, Compositions and	)	Commissioner of Patents and Trademarks,
		Methods for the Endocytic	)	Washington, D.C. 20231, on
		Presentation of Immunosuppressive	)	<u>December 24, 2002</u>
		Factors	)	<u>Christine Hughey</u>
Examiner	:	P. Nolan	)	Christine Hughey

RECEIVED

JAN 06 2003

AMENDMENT AND RESPONSE TO OFFICE ACTION

TECH CENTER 1600/2900

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

In response to the Office Action dated June 25, 2002, applicant submits the following response:

Remarks

Claims 1 - 7 and 21 - 28 are pending in the application.

Rejection of the Claims under 35 USC 112(1)

Claims 1 - 7 and 21 - 28 are rejected under 35 USC 112(1) as containing subject matter not described in the specification. The Office Action states that there is no support for the phrase "is derived from a protein responsible for an autoimmune disease" as recited in claim 1. However, applicant respectfully disagrees. On page 8, lines 19 - 22 of WO 00/001732 (PCT Publication from which this application is a U.S. national application), states:

Accordingly, efficient FcR mediated presentation of appropriate TCR antagonists or agonists (wherein the agonists may be derived from autoantigenic polypeptides or